Share Name |
Share Symbol |
Market |
Type |
Share ISIN |
Share Description |
Futura Medical Plc |
LSE:FUM |
London |
Ordinary Share |
GB0033278473 |
ORD 0.2P |
|
Price Change |
% Change |
Share Price |
Bid Price |
Offer Price |
High Price |
Low Price |
Open Price |
Shares Traded |
Last Trade |
|
0.00 |
0.0% |
14.50 |
14.00 |
15.00 |
14.97 |
14.50 |
14.50 |
24,277 |
08:00:29 |
Industry Sector |
Turnover (m) |
Profit (m) |
EPS - Basic |
PE Ratio |
Market Cap (m) |
Pharmaceuticals & Biotechnology |
0.0 |
-11.1 |
-4.4 |
- |
36 |
Futura Medical Share Discussion Threads

Showing 17026 to 17048 of 19725 messages
Date | Subject | Author | Discuss |
---|
16/7/2019 10:15 | The question must be whether any potential licensee decides it is better to conclude a deal at these levels? If not, pay possibly vast amounts more,in a bidding war with other players.
The product is first major ED breakthrough in 20 years.
Is applied topically
Works within 5 to 10 mins v up to one hour for Viagra,Cialis etc.
Please form an orderly queue. |  j777j | |
16/7/2019 09:59 | But why wait till Sept/Dec when the writing is on the wall now about the potential |  tiananmen | |
16/7/2019 09:52 | Assuming regulatory approval for both MED2005 and TPR100 (the odds of which are getting ever more short) this will be in the pounds not pence, however I cant find an explanation for the last few days rise.
MED2005 is well off until end of year (earliest end Oct, probably later) and nothing is expected from Thornton & Ross on TPR100 Until Sept earliest.
So there is something else out there – Good obviously...but what? |  ragnarr | |
16/7/2019 09:04 | 135k gone through. Someone is confident! |  ch4p_85 | |
16/7/2019 08:32 | From where I am looking Singer N+1 forecast $90 million in upfront and milestone payments for Europe and USA. That is fairly near to the entire market cap alone.
They also forecast 15% royalties.
The consensus is the med gel can reach $1 billion in annual sales.
Does not take much to work out how many royalties will come in at 25% of that ( $37.5 million pa) up to 100%($150 million pa.)
Big big numbers.
We also know Eli Lilly bought the remaining 50% its Cialis joint venture from Icos for $2.3 billion.
That after having paid $75 million upfront after only a patchy phase 2 trial. |  j777j | |
16/7/2019 08:22 | UP 768%+ since the beginning of this year - keep chasing ;-) |  5oletrader | |
16/7/2019 08:21 | Looks like it doesn’t it! DYOR |  qs99 | |
16/7/2019 08:08 | something definitely going on ? |  ragnarr | |
16/7/2019 07:54 | takeover bid imminent = explosionnnn to £1++ quickly |  ih_116147 | |
16/7/2019 07:27 | There is no doubt that as we get closer to november,awareness will rise. |  j777j | |
16/7/2019 06:56 | will we see some more fireworks today? |  qs99 | |
15/7/2019 14:44 | well it is being well bought IMO! |  qs99 | |
15/7/2019 14:25 | For all those getting carried away, Lombard odier haven't gone away.every time price moves up on big volume,they reduce.Cant be long before their next rns. |  wantage | |
15/7/2019 14:17 | double wow |  qs99 | |
15/7/2019 14:08 | wow, there really is some good support here, well done all those that have kept the faith! |  qs99 | |
15/7/2019 12:41 | Another MONSTER buying opp guys is the Novartis Spin-off Mereo Biopharma (MPH.L) which trading below cash balance the current market cap is only £44 million thats nothing for a company with 3 x Phase 3 ready Programs . Good news out today on that undiscovered stock , check it out guys you will like it .
MPH.L trading at 44p
Mereo BioPharma---Focus shifts back to imminent data
hxxps://www.trinitydelta.org/research-notes/focus-shifts-back-to-imminent-data/
rNPV valuation of 506p/share We re-introduce our estimates and valuation of Mereo following the completion of the OncoMed transaction. We value Mereo using a rNPV methodology of its four leading assets at £541m ($704m), equivalent to 506p/share or $25.59/ADS (fully diluted). As indicated, there are multiple significant catalysts due in 2019, which could lead to major re-ratings of the shares. |  ih_116147 | |
15/7/2019 12:16 | It is so clear that this company is very undervalued, if you think that they can wipe out the competition Viagra. By the end of the year is certainly to be expected with a BIG Deal or company Takeover! Definitely! |  firstman | |
15/7/2019 12:04 | I think some know more and cover up piece by piece. |  firstman | |
15/7/2019 11:58 | Bid could be in the £1-1.20 range |  ih_116147 | |
15/7/2019 11:57 | You will be rewarded with Brucie Bonus |  kop202 | |
15/7/2019 11:46 | Does Fum manage to remain independent and retain all the rights,or will someone just snap it up?
Let's face it there are not that many co's around with a low market cap that might deliver a blockbuster drug ($1 billion sales.)
We will find out soon enough. |  j777j | |
15/7/2019 11:42 | RALLYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY see you at £1.50++ by year end |  ih_116147 | |
15/7/2019 11:38 | One also has to assume that Liberum coming to their 140p trials great success valuation,discussions with Fum management would have indicated the possible sums involved.
Singer N+1 had already estimated upfront and milestone payment of $90 million covering europe and the USA. |  j777j | |